Beleaguered Merck looks to future
679017
A week after saying it was withdrawing its $2.5 billion arthritis drug Vioxx from the market and losing a quarter of its stock market value as a result, Merck &amp; Co. will try to dodge the storm clouds and turn its attention tomorrow to a brighter subject with the official opening of its Boston research lab.
652619
Bad press from Vioxx shouldn't overshadow the company's new offering.
175709
Investors care more about the drugmaker's future than its Q4 results.
77029
Now that Merck &amp; Co.&#39;s $2.5 billion annual revenues from anti-inflammatory COX-2 inhibitor VIOXXÂ® are history, the next question is what happens to the even greater amount of money ($3.
334636
With its stock plunging, the drug giant Merck has adopted a plan that could give its top executives big bonuses if the company is taken over.
200299
The recall of Vioxx--an arthritis treatment taken by millions of people--is a disaster for everyone. Of course it&#39;s bad news for Merck (nyse: MRK - news - people), the drug&#39;s maker.
211428
Merck &amp; Co.'s chairman and chief executive Raymond Gilmartin yesterday defended his firm's handling of earlier health warnings about Vioxx and said he was &quot;stunned&quot; when he learned two weeks ago that a Merck clinical trial had confirmed the drug could cause strokes and heart attacks.
551275
Merck adopted the plan at a time that its stock is down sharply and its ability to thrive as an independent company is uncertain.
434277
The market might overlook the drug maker's promising programs.
132631
NEW YORK - Inconclusive trial results for Merck&#39;s Zocor might turn out to be a boost for the company&#39;s next cholesterol medicine, Vytorin.
387905
The beleaguered drug giant&#39;s lowered forecast isn&#39;t as bad as Wall Street expected. But investors still await the long-term prognosis.
575614
Merck and Schering report bad news, but how much will it affect sales?
201667
WALL STREET analysts last night said a second experimental pain killer under development by Merck, the American drugs maker, could be delayed until 2007, after regulators asked for more information on the medicineâs safety.
597746
Industry analysts are predicting US regulators this month will refuse to approve Merck &amp; Co.&#39;s new arthritis drug until at least 2006 because of heart attacks linked to its recalled sister drug Vioxx.
746711
At a time when the drug industry is  being pounded with recalls and government investigations while  turning out few major new drugs, French drugmaker  Sanofi-Aventis appears to have a big winner on its hands.
146686
Drug companies rushing to fill the vacuum left by Merck &amp; Co.'s withdrawal of its best-selling arthritis drug Vioxx are flooding the airwaves with competing advertising claims that are bewildering many patients.
162345
Merck & Co. Inc.  shares could rise to $70 by 2010 if the drugmaker continues to deliver on its promise of double-digit earnings growth, Barron's said in its October 29 edition.